Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Breast 1

Conditions

Uveal Melanoma 2Triple Negative Breast Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Melanoma 1Breast Neoplasms 1

Interventions

montanide ISA 51 3Temozolomide 3Ipilimumab 3Interleukin-2 3sargramostim 2incomplete Freund's adjuvant 2glembatumumab vedotin 2aldesleukin 2Vorinostat 2Sunitinib 2Paclitaxel 2MART-1 Antigen 2Lenalidomide 2Dacarbazine 2Cyclophosphamide 2Carboplatin 2CR011-vcMMAE 2Amplified Fragment Length Polymorphism Analysis 2trametinib 1poly ICLC 1omipalisib 1fludarabine phosphate 1fludarabine 1flt3 ligand protein 1entinostat 1cixutumumab 1cediranib 1cabozantinib 1aflibercept 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Uveal Melanoma × CR011-vcMMAE × Clear all
NCT02363283 2020-08-21

Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
37 enrolled 12 charts
Dermatologic

Uveal Melanoma

NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡